KATHLEEN BREWER: Open Payments
NPI 1720497951 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$739 in 40 payments from 11 companies in 2025. Trend: 2023 $905 · 2024 $896 · 2025 $739
Food & beverage: $739
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 11 | $177 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $98 |
| Alnylam Pharmaceuticals Inc. | 5 | $83 |
| Merck Sharp & Dohme LLC | 4 | $80 |
| Novartis Pharmaceuticals Corporation | 4 | $70 |
| Philips North America LLC | 3 | $54 |
| BridgeBio Pharma, Inc. | 3 | $51 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $39 |
| AstraZeneca Pharmaceuticals LP | 2 | $33 |
| United Therapeutics Corporation | 1 | $32 |
Products named: JARDIANCE, VYNDAQEL, AMVUTTRA, ELIQUIS, LEQVIO, VERQUVO, Attruby, Kerendia.
Industry payments across MS — which companies pay providers there.
